Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 1998

View Archived Issues

New LTB4 receptor antagonists disclosed by Boehringer Ingelheim

Allergan reports new compounds acting as retinoid antagonists or inverse agonists

Cytokine production inhibitors for inflammatory disorders in development at Ortho-McNeil

Novo Nordisk describes novel muscarinic cholinergic receptor modulators

SmithKline Beecham announces setback in RA trials

Development of new beta-lactamase inhibitors revealed by Japanese laboratories

Gene transfer of plasmid DNA encoding TGF-beta for suppressing inflammation in arthritis

Myocardial protective effects of JTV-519 demonstrated in isolated rat hearts

FDA gives go-ahead for first human study of VEGF-2 gene therapy

OPC-31260: potential utility in cirrhosis patients with impaired water handling

NO donor effective in canine ischemic liver injury model

FR-167653 proves effective against ischemic liver damage

Several NDAs up for review by FDA oncologic advisory committee in January

Anti-HIV, antimalarial agents available for licensing from NIH

New indications for Prograf scheduled for FDA advisory committee review

Zila's OraTest to be reviewed by FDA advisory committee next month

Water-soluble anticancer compounds available for licensing from NIH

BioChem Pharma and BioChem Therapeutic merge operations

IND filed by Cell Pathways for new SAAND; lead compound Prevatac enters clinic for sixth indication

U.S. patent improves proprietary position of Alexion in C5 complement inhibition

New blood pool MR contrast agent presented by Mallinckrodt

Ajinomoto prepares potent, water-soluble combretastatin analogues

Vascular-selective potassium channel openers designed at Kanebo

Warner-Lambert and BioChem Therapeutic seek potent and selective thrombin inhibitors

Modified TAPET organisms with tumor-targeting properties but reduced virulence and side effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...